Summit Therapeutics Inc. 4

Co-Chief Executive Officer Mahkam Zanganeh, via her revocable trust, bought 100,000 shares of Summit Therapeutics Inc. common stock at $14.60 per share on 2026-06-04.

On 2026-06-04, Co-Chief Executive Officer Mahkam Zanganeh, through the Mahkam Zanganeh Revocable Trust, purchased 100,000 shares of Summit Therapeutics Inc. common stock at $14.60 per share for an aggregate cost of approximately $1.46 million, increasing the trust’s directly reported holdings to 25,824,474 shares. In addition, the Form 4 reflects substantial indirect holdings via an immediate family member (76,680 shares), her spouse (570,073,879 shares), and the Shaun Zanganeh Irrevocable Trust (10,199,776 shares), although Zanganeh disclaims beneficial ownership of these indirect positions except to the extent of any pecuniary interest. The filing emphasizes that the inclusion of these indirect holdings should not be construed as an admission of full beneficial ownership for Section 16 or other purposes.

Filing Facts

CIK

1599298

Ticker

SMMT

Form

4

Source Type

sec

Accession

0001507650-26-000005

Alert Tier

8